Expanded Access to RXDX-105 for Cancers With RET Alterations

Summary

Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications

No indication recorded.